Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression

scientific article published on 13 January 2012

Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4238/2012.JANUARY.13.1
P8608Fatcat IDrelease_ttcovhfokvg37puvnpogulpguy
P698PubMed publication ID22290468
P5875ResearchGate publication ID221791896

P2093author name stringJ Huang
M Sun
M Qin
G-F Li
C-X Yang
G-S Li
T-L Qian
Y-Q Han
P2860cites workDifferential effects of valproic acid on growth, proliferation and metastasis in HTB5 and HTB9 bladder cancer cell linesQ39867753
P433issue1
P304page(s)77-86
P577publication date2012-01-13
P1433published inGenetics and Molecular ResearchQ15762471
P1476titleSodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression
P478volume11

Reverse relations

cites work (P2860)
Q60305702Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
Q35845089Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis
Q36574546Butyrate histone deacetylase inhibitors.
Q37039303Enhanced suppression of proliferation and migration in highly-metastatic lung cancer cells by combination of valproic acid and coumarin-3-carboxylic acid and its molecular mechanisms of action
Q37114711Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail
Q90398667Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties
Q51599902N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells.
Q28595847Sodium channel-inhibiting drugs and cancer survival: protocol for a cohort study using the CPRD primary care database
Q26772803Therapeutic Value of Voltage-Gated Sodium Channel Inhibitors in Breast, Colorectal, and Prostate Cancer: A Systematic Review
Q53410584Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.
Q36335796Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation
Q36606222Valproic acid inhibits the invasion of PC3 prostate cancer cells by upregulating the metastasis suppressor protein NDRG1.

Search more.